

LIST OF TABLES

Figures

Figure 2.1 Top ten countries and the percentages of individuals who participated in DNA RNA 2013

Figure 2.2 Regions and associated percentages of individuals who participated in DNA RNA 2013

Figure 2.3 Professional positions (and %) of individuals who participated in DNA RNA 2013

Figure 2.4 Participants' 'years of experience' in the use of techniques to extract DNA and RNA (Study DNA RNA 2013)

Figure 2.5 Organisation types indicated by participants in DNA RNA 2013

Figure 2.6 Field types indicated by participants in DNA RNA 2013

Figure 3.1 Current nucleic acid forms studied by participants in DNA RNA 2013

Figure 3.2 Nucleic acid forms anticipated to be studied in three years from now, by participants in DNA RNA 2013

Figure 4.1 Current techniques used for the isolation of DNA or RNA, indicated by participants in DNA RNA 2013

Figure 4.2 Future techniques used for the isolation of DNA or RNA, indicated by participants in DNA RNA 2013

Figure 5.1 Overall current use of kit and non-kit methods for the isolation of DNA and RNA, reported by participants in DNA RNA 2013

Figure 5.2 Overall anticipated use of kit and non-kit methods for the isolation of DNA and RNA in three years from now, reported by participants in DNA RNA 2013

Figure 5.3 Current use of kits for the isolation of all nucleic acid forms, reported by participants in DNA RNA 2013

Figure 5.4 Anticipated use of kits for the isolation of all nucleic acid forms in three years from now, reported by participants in DNA RNA 2013

Figure 5.5 Current use of non-kit methods for the isolation of all nucleic acid forms, reported by participants in DNA RNA 2013

Figure 5.6 Anticipated use of non-kit methods for the isolation of all nucleic acid forms in three years from now, reported by participants in DNA RNA 2013

Figure 5.7 Current use of other isolation methods for all NA forms, reported by participants in DNA RNA 2013

Figure 5.8 Use of other isolation methods for all NA forms in three years from now, reported by participants in DNA RNA 2013

Figure 5.9 Current isolation methods for genomic DNA, reported by participants in DNA RNA 2013

Figure 5.10 Anticipated use of isolation methods for genomic DNA in three years from now, reported by participants in DNA RNA 2013

Figure 5.11 Current isolation methods for microRNA, reported by participants in DNA RNA 2013

Figure 5.12 Isolation methods anticipated to be used for microRNA in three years from now, reported by participants in DNA RNA 2013

Figure 5.13 Current isolation methods for microRNA, reported by participants in DNA RNA 2013

Figure 5.14 Isolation methods anticipated to be used for microRNA in three years from now, reported by participants in DNA RNA 2013

Figure 5.15 Current isolation methods for ribosomal RNA, reported by participants in DNA RNA 2013

Figure 5.16 Isolation methods anticipated to be used for ribosomal RNA in three years from now, reported by participants in DNA RNA 2013

Figure 5.17 Current isolation methods for SiRNA, reported by participants in DNA RNA 2013

Figure 5.18 Isolation methods anticipated to be used for SiRNA in three years from now, reported by participants in DNA RNA 2013

Figure 5.19 Current isolation methods for snRNA, reported by participants in DNA RNA 2013

Figure 5.20 Isolation methods anticipated to be used for snRNA in three years from now, reported by participants in DNA RNA 2013

Figure 5.21 Current isolation methods for tRNA, reported by participants in DNA RNA 2013

Figure 5.22 Isolation methods anticipated to be used for tRNA in three years from now, reported by participants in DNA RNA 2013

Figure 5.23 Main methods used for the isolation of DNA and RNA, reported by participants in DNA RNA 2013

Figure 5.24 Changes in the use of Kit and Non-Kit methods over the next three years (2013 – 2016), reported by participants in DNA RNA 2013

Figure 6.1 The top five current solution phase (non-kit) methods for the extraction of DNA/RNA, reported by participants in DNA RNA 2013

Figure 6.2 Top current preferred suppliers of solution phase (non-kit) products for the extraction of DNA/RNA, reported by participants in DNA RNA 2013

Figure 6.3 The top five preferred solution-phase (non-kit) methods for the isolation of DNA/RNA in three years from now, reported by participants in DNA RNA 2013

Figure 6.4 Top preferred suppliers of solution phase (non-kit) methods for the isolation of DNA/RNA in three years from now, reported by participants in DNA RNA 2013

Figure 6.5 Advantages of solution phase (non-kit) methods for the isolation of DNA/RNA, reported by participants in DNA RNA 2013

Figure 6.6 Disadvantages of solution phase (non-kit) methods for the isolation of DNA/RNA, reported by participants in DNA RNA 2013

Figure 7.1 Top current preferred solid-phase (non-kit) methods for the isolation of DNA/RNA, reported by participants in DNA RNA 2013

Figure 7.2 Top current preferred suppliers of solid-phase (non-kit) methods for the isolation of DNA/RNA, reported by participants in DNA RNA 2013

Figure 7.3 Top anticipated preferred solid-phase (non-kit) methods for the isolation of DNA/RNA in three years from now, reported by participants in DNA RNA 2013

Figure 7.4 Top anticipated preferred suppliers of solid-phase (non-kit) methods for the isolation of DNA/RNA in three years from now, reported by participants in DNA RNA 2013

Figure 7.5 Advantages of solid-phase (non-kit) methods for the isolation of DNA/RNA, reported by participants in DNA RNA 2013

Figure 7.6 Disadvantages of solid-phase (non-kit) methods for the isolation of DNA/RNA, reported by participants in DNA RNA 2013

Figure 8.1 Preferred current suppliers of kits for isolating DNA, reported by participants in DNA RNA 2013

Figure 8.2 Preferred anticipated future suppliers of kits for isolating DNA, reported by participants in DNA RNA 2013

Figure 8.3 Current preferred suppliers of kits for isolating RNA, reported by participants

in DNA RNA 2013

Figure 8.4 Future preferred suppliers of kits for isolating RNA, reported by participants in DNA RNA 2013

Figure 8.5 The advantages of using DNA and RNA isolation kits, reported by participants in DNA RNA 2013

Figure 8.6 The disadvantages of using DNA and RNA isolation kits, reported by participants in DNA RNA 2013

Figure 9.1 The use of automated methods for the isolation of DNA and RNA, reported by participants in DNA RNA 2013

Figure 9.2 The current percentage of DNA and RNA isolation methods that are automated, indicated by participants in DNA RNA 2013 who use automated methods

Figure 9.3 The percentage of DNA/RNA isolation methods anticipated to be automated in three

years from now, indicated by participants in DNA RNA 2013 who use automated methods

Figure 9.4 Top five preferred companies for the automation of DNA isolation, indicated by participants in DNA RNA 2013 who currently use automated methods

Figure 9.5 Top three preferred companies for the automation of RNA isolation, indicated by participants in DNA RNA 2013 who currently use automated methods

Figure 10.1 Top current applications associated with DNA and RNA isolation methods, used by participants in DNA RNA 2013

Figure 10.2 Top applications associated with DNA and RNA isolation methods that are anticipated to be used in three years from now, by participants in DNA RNA 2013

Figure 11.1 Top therapeutic areas associated with DNA and RNA isolation methods used by participants in DNA RNA 2013

Figure 12.1 Top specialist areas associated with the use of DNA and RNA isolation methods, reported by participants in DNA RNA 2013

Figure 12.2 Top purposes or reasons associated with the use of DNA and RNA isolation methods, reported by participants in DNA RNA 2013

Figure 13.1 Top study samples processed using DNA and RNA isolation methods used by participants in DNA RNA 2013

Figure 14.1 The study of disease biomarkers associated with the use of DNA and RNA isolation methods, indicated by participants in DNA RNA 2013

Figure 14.1 Top current disease biomarkers associated with the use of DNA and RNA isolation methods, indicated by participants in DNA RNA 2013

Figure 14.2 Top disease biomarkers associated with the use of DNA and RNA isolation methods anticipated to be studied three years from now, indicated by participants in DNA RNA 2013

Figure 14.3 Top disease biomarkers clinical utilities relating to their use of DNA and RNA isolation methods, indicated by participants in DNA RNA 2013

Figure 15.1 Per-sample non-kits costs and associated percentages of end-users, indicated by participants in DNA RNA 2013

Figure 15.2 Per-sample kits costs and associated percentages of end-users, indicated by participants in DNA RNA 2013

Figure 15.3 Budget costing areas relating to the isolation of DNA and RNA, indicated by participants in DNA RNA 2013

Figure 16.1 Top three consumables (by cost) in the isolation of DNA or RNA, indicated by participants in DNA RNA 2013

Appendix 1. Top three consumables (by cost) used in the isolation of DNA or RNA, indicated by participants in DNA RNA 2013

Tables

Table 2.1 Countries, percentages and numbers (No) of individuals who participated in DNA RNA 2013

Table 2.1 Countries, percentages and numbers (No) of individuals who participated in DNA RNA 2013

Table 2.2 Regions, associated percentages and numbers (No) of individuals who participated in DNA RNA 2013

Table 2.3 Professional positions (% and number, No) of individuals who participated in DNA RNA 2013

Table 2.4 Participants' 'years of experience' in the use of techniques to extract DNA and RNA (Study DNA RNA 2013)

Table 2.4 Participants' 'years of experience' in the use of techniques to extract DNA and RNA (Study DNA RNA 2013)

Table 2.5 Organisation types indicated by participants in DNA RNA 2013

Table 2.6 Field types indicated by participants in DNA RNA 2013

Table 2.7 Other field types indicated by participants in DNA RNA 2013

Table 3.1 Current nucleic acid forms (as % total) and those anticipated to be studied three years from now (as a % of total), indicated by participants in DNA RNA 2013

Table 6.1 Current solution-phase (non-kit) methods for the isolation of DNA/RNA, reported by participants in DNA RNA 2013

Table 6.2 Current preferred suppliers of solution phase (non-kit) products for the extraction of DNA/RNA, reported by participants in DNA RNA 2013

Table 6.3 Preferred solution-phase (non-kit) methods for the isolation of DNA/RNA in three years from now, reported by participants in DNA RNA 2013

Table 6.4 Preferred suppliers of solution phase (non-kit) methods for the isolation of DNA/RNA in three years from now, reported by participants in DNA RNA 2013

Table 6.5 Advantages of solution phase (non-kit) methods for the isolation of DNA/RNA, reported by participants in DNA RNA 2013

Table 6.6 Disadvantages of solution phase (non-kit) methods for the isolation of DNA/RNA, reported by participants in DNA RNA 2013

Table 7.1 Current preferred solid-phase (non-kit) methods for the isolation of DNA/RNA, reported by participants in DNA RNA 2013

Table 7.2 Current preferred suppliers of solid-phase (non-kit) methods for the isolation of DNA/RNA, reported by participants in DNA RNA 2013

Table 7.3 Anticipated preferred solid-phase (non-kit) methods for the isolation of DNA/RNA in three years from now, reported by participants in DNA RNA 2013

Table 7.4 Anticipated preferred suppliers of solid-phase (non-kit) methods for the isolation of DNA/RNA in three years from now, reported by participants in DNA RNA 2013

Table 7.5 Advantages of solid-phase (non-kit) methods for the isolation of DNA/RNA, reported by participants in DNA RNA 2013

Table 7.6 Disadvantages of solid-phase (non-kit) methods for the isolation of DNA/RNA, reported by participants in DNA RNA 2013

Table 8.1 Preferred current suppliers of kits for isolating DNA, reported by participants in DNA RNA 2013

Table 8.2 Preferred kits currently for isolating DNA, reported by participants in DNA RNA 2013

Table 8.3 Preferred anticipated future suppliers of kits for isolating DNA, reported by participants in DNA RNA 2013

DNA RNA 2013

Table 8.4 Future preferred kits for isolating DNA reported by participants in DNA RNA 2013

Continued Table 8.4 Future preferred kits for isolating DNA, reported by participants in DNA RNA 2013 Continued Table 8.4 Future preferred kits for isolating

DNA, reported by participants in DNA RNA 2013

Table 8.5 Current preferred suppliers of kits for isolating RNA, reported by participants in DNA RNA 2013

Table 8.6 Current preferred kits for isolating RNA, reported by participants in DNA RNA 2013

Table 8.7 Future preferred suppliers of kits for isolating RNA, reported by participants in DNA RNA 2013

Table 8.8 Future preferred suppliers of kits for isolating RNA, reported by participants in DNA RNA 2013

Table 9.1 Preferred companies for the automation of DNA isolation, indicated by participants in DNA RNA 2013 who currently use automated methods

Table 9.2 Automation platforms and companies for DNA isolation, indicated by participants in DNA RNA 2013

Table 9.3 Preferred companies for the automation of RNA isolation, indicated by participants in DNA RNA 2013 who currently use automated methods

Table 9.4 Automation methods and companies for RNA isolation, indicated by participants in DNA RNA 2013

Table 10.1 Current applications associated with DNA and RNA isolation methods, used by participants in DNA RNA 2013

Table 10.2 Applications associated with DNA and RNA isolation methods that are anticipated to be used in three years from now, by participants in DNA RNA 2013

Table 11.1 Therapeutic areas associated with DNA and RNA isolation methods used by participants in DNA RNA 2013

Table 12.1 Specialist areas associated with the use of DNA and RNA isolation methods, reported by participants in DNA RNA 2013

Table 12.2 Purposes or reasons associated with the use of DNA and RNA isolation methods, reported by participants in DNA RNA 2013

Table 13.1 Study samples processed using DNA and RNA isolation methods used by participants in DNA RNA 2013

Table 14.1 Current disease biomarkers associated with the use of DNA and RNA isolation methods, indicated by participants in DNA RNA 2013

Table 14.2 Disease biomarkers associated with the use of DNA and RNA isolation methods anticipated to be studied three years from now, indicated by participants in DNA RNA 2013

Table 14.3 Disease biomarkers clinical utilities relating to their use of DNA and RNA isolation methods, indicated by participants in DNA RNA 2013

Table 15.1 Per-sample non-kits costs and associated percentages of end-users, indicated by participants in DNA RNA 2013

Table 15.2 Per-sample kits costs and associated percentages of end-users, indicated by participants in DNA RNA 2013

Table 15.3 Budget costing areas relating to the isolation of DNA and RNA, indicated by participants in DNA RNA 2013

Table 15.4 Future overall budget relating to the isolation of DNA and RNA, indicated by participants in DNA RNA 2013

Table 16.1 Top three consumables (by cost) used in the isolation of DNA or RNA, indicated by participants in DNA RNA 2013